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Abstract
Background The FOXP3 mRNA expression and the other
regulatory T cell-related molecules were investigated and
compared with clinicopathological parameters in human
primary breast cancer.
Method This study included 136 breast cancer patients
operated in our department from 2003 to 2006. Total RNA
was extracted from frozen normal breast and breast cancer
tissues, and the expression of FOXP3, IL-10, TGF1 and
CCL22 mRNA was evaluated using quantitative real-time
RT-PCR.
Result FOXP3, IL-10, TGF1 and CCL22 mRNA expres-
sions were signiWcantly higher in cancer tissue than in nor-
mal tissue, not only at pT1, 2, and 3 stages but also at the
DCIS stage. There were positive correlations between
FOXP3 and IL-10, FOXP3 and TGF1, as well as FOXP3
and CCL22 mRNA expressions, respectively. FOXP3 and
IL-10 mRNA expressions were signiWcantly upregulated in
PgR-negative or HER2-positive tumors.
Conclusion These results suggest that regulatory T cells
are involved in tumor onset and progression in human pri-
mary breast cancer, possibly contributing to poor prognosis
of patients with breast cancer.
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Introduction
Regulatory T (Treg) cells have been highlighted in tumor
immunology [1, 2]. Although Treg cells protect hosts in
vivo against the development of autoimmunity, they also
suppress the reaction of lymphocytes to tumor antigens in
some malignant neoplasms [3]. This suppression helps the
neoplasms to escape from the host immune system [4].
Therefore, to explore the existence of Treg cells in cancer
patients and the involvement of Treg cells in tumor onset
and progression is an important issue to be clariWed. It has
been reported that Treg cells are increased in peripheral
blood in patients with non-small cell lung cancer [5, 6] and
gastrointestinal malignancies [7], in sentinel lymph nodes
in breast cancer [8], and in tumor nodules in head and neck
[9], prostate [10], and breast [11, 12] cancers. Although
these reports have suggested Treg cell involvement in
tumor progression, it still requires more clinical samples to
deWne Treg cell signiWcance in tumor onset and progression
of breast cancer.
Treg cells are originally characterized by the co-expres-
sion of CD4 and CD25 molecules [13, 14]. Treg cell activ-
ity is known to be closely associated with the expression
of forkhead/winged helix transcription factor, Foxp3.
Although Foxp3 is not induced upon activation of CD25-
T cells, naive CD4+CD25-T cells transform into Treg cells
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gene expression [15, 16]. Recently, CD4+CD25-T cells
were induced to express FOXP3 and achieve regulatory
function by stimulation through the T-cell receptor (TCR)
in humans [17] and transforming growth factor- (TGF)
in mice [18]. From these Wndings, FOXP3 can be consid-
ered to be a critical regulator of Treg cell development and
function in mice and humans. Although the precise mecha-
nisms of immunosuppression by Treg cells remain to be
determined, Treg cells can inhibit immune cell functions
either directly through cell-to-cell contact or indirectly
through the secretion of anti-inXammatory mediators such
as IL-10 and TGF1. The antigens recognized by Treg cells
appear to be self, tissue-speciWc antigens [19]. More
recently, the molecular mechanisms of Treg cell migration
have been precisely demonstrated: Treg cells express che-
mokine receptor CCR4 and show demonstrable chemotac-
tic responses to the CCR4 ligands CCL22 and CCL17 [20].
Based on the above Wndings, we studied Treg cell
involvement in the onset and progression of 136 human
breast cancer samples by using RT-PCR for FOXP3, IL-10,
TGF1 and CCL22 mRNA expressions. We analyzed the
relationship between these molecular expressions and
known clinicopathological parameters of prognosis such as
the size of the primary tumor, histologic tumor grade,
lymph node status, estrogen (ER) and progesterone receptor




Adult female patients with primary breast cancer who
underwent breast surgery at the Hiroshima University Hos-
pital between 2003 and 2006 were enrolled in this study.
The study was approved by the institutional review board
of Hiroshima University Hospital, and written informed
consent was obtained from all enrolled patients. Normal
breast tissues were taken from a site distant from the tumor-
ous lesion (n = 11).
RT-PCR
Total RNA was extracted from stored tumor tissues with an
RNeasy Mini Kit (QIAGEN, Hilden, Germany). DNase
treatment was performed with the RNase-Free DNase Set
(QIAGEN) to avoid ampliWcation of contaminating geno-
mic DNA. The quality and quantity of the obtained total
RNA were determined by absorbance at 260 and 280 nm
and were adjusted to a concentration of 0.10 g/L. In
addition, the integrity of RNA in each preparation was
tested by RT-PCR of glyceraldehyde-3-phosphate dehydro-
genase (GAPDH). The prepared total RNA served as the
template for Wrst-strand cyclic DNA (cDNA) synthesis
using Ready-To-Go™ You-Prime-First-Strand Beads
(Amersham Pharmacia Biotech Inc., Piscataway, NJ, USA)
with 0.5 g of Oligo (dT)15 primer (Novagen, Darmstadt,
Germany) according to the manufacturer’s instructions.
Each cDNA product was diluted tenfold with RNase-free
water to avoid inhibition of the PCR reaction by reagents
used in RNA extraction or reverse transcription. For rela-
tive quantiWcation by PCR, each cDNA product was
analyzed at a Wnal Mg2+ concentration of 3 mM in a
LightCycler with software (version 3.5; Roche Molecular,
Mannheim, Germany) by using the FastStart DNA Master
SYBR Green I Kit (Roche Diagnostics, Mannheim, Ger-
many). For each primer pair, a standard curve was devel-
oped. The PCR condition was 95°C for 10 min for the
initial denaturation, followed by 35 cycles of 1 second at
95°C, 10 s at 60°C, and 10 s at 72°C, followed by a melting
program (at 60–95°C) to check the proper melting tempera-
ture of the product. Annealing temperatures and elongation
times were optimized for primer generation and exclusion
of artifacts. Primers for FoxP3, IL-10, TGF1, CCL22
and GAPDH were from Search-LC GmbH (Heidelberg,
Germany).
All clinical samples were ampliWed by PCR, and the
quality of ampliWcation was checked with Light Cycler R
software (version 3.5; Idaho Technology Inc., Salt Lake
City, UT, USA) by calculating the ratio of the crossing
point (threshold cycle number for the beginning of the
exponential phase) and the logarithm concentration of the
ampliWed copy number for each standard sample [21].
Statistical analysis
The Mann–Whitney U test and Kruskal–Wallis test were
used when testing categorical or continuous categorical
data against categories. Spearman’s rank correlation and
simple regression analysis were used to identify associa-
tions in the expression of each parameter with StatView
software (version 5 for Windows; Abacus Concepts, Inc.,
London, UK). P values <0.05 were considered signiWcant.
Results
Patient and tumor characteristics
Background data of patients with regard to age, histologic
type of tumor, pathologic (p)TNM classiWcation, ER, PgR,
HER2, and lymphatic and vascular invasion status are
summarized in Table 1. The enrolled patients were
58.1 § 13.0 years old (mean § standard deviation; range123
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status, 84 had pT1 status, and 40 patients pT2 or pT3 status.
Ninety-four patients had pN0 status, and 37 had pN1, N2,
and N3 status. Seventy-nine percent of the tumors were
determined to be invasive ductal carcinomas according to
standard histopathology (hemtoxylin and eosin staining).
Greater than 70% of the tumors expressed estrogen (88%)
or progesterone (75%) receptors. Twenty-one percent of the
patients had positive HER2 status and 78% of the patients
negative HER2 status according to HercepTest-immuno-
staining and Xuorescence in situ hybridization (FISH).
One-third of the patients had ScarV–Bloom–Richardson
grades 1, 2, or 3. Approximately two-thirds of the patients
showed a lymphatic invasion score of 0, and none of the
patients had vascular invasion.
FOXP3 and IL-10 mRNA expressions
We used quantitative RT-PCR to analyze FOXP3 and
IL-10 mRNA expressions in breast cancer tissue and com-
pared expression levels against each clinicopathological
factor (Table 2). There was no correlation between
FOXP3 mRNA expression and pT category (data not
shown). However, FOXP3 mRNA expression in cancer
tissue was signiWcantly upregulated when compared with
normal breast tissue expression (P < 0.01), even at the
ductal carcinoma in situ (DCIS) stage (P < 0.01) (Fig. 1a).
Similar results were obtained in IL-10 mRNA expression
(Fig. 1b). The upregulation of FOXP3 and IL-10 mRNA
expressions persisted at the pT1 and pT2, 3 stages
(P < 0.01) (Fig. 1a, b), showing the expression levels of
7.4 § 10.9, 170.5 § 207.9, 205.1 § 184.1, 165.7 § 200.9 and
170.3 § 231 copies in FOXP3 mRNA, and 61.73 § 118.4,
Table 1 Patients and tumor charateristics






Mean § SD 58.1 § 13.0
Range 33–88
pT category
pTis (DCIS) 12 9
pT1 84 62
pT2 pT3 40 29
pN category
pN0 94 69
pN1 pN2 pN3 37 27
pNX 5 4
Tumor histologic type
Noninvasive ductal carcinoma 12 9
Invasive ductal carcinoma 107 79
Special types 17 13
Tumor grade (SBR)
Grade 1 31 23
Grade 2 51 38

















Table 2 Relationship between FOXP3, IL-10, TGF and clinicopatho-
logical factors (only correlative parameters and their values)
SD standard deviation, SBR ScarV–Bloom–Richardson, PgR proges-
terone receptor
n (%) Mean § SD P value
FOXP3
Tumor grade (SBR)
Grade 1 31 (22%) 108.8 § 129.6
Grade 2 51 (38%) 152.2 § 162.3
Grade 3 53 (39%) 222.9 § 267.6 0.0981
Hormone receptor status
PgR-positive 102 (75%) 144.2 § 180.8
PgR-negative 34 (25%) 249.5 § 260.9 0.0075
HER2 status
Negative 106 (79%) 150.4 § 187.3
Positive 28 (21%) 255.0 § 234.6 0.007
IL-10
pN category
pN0 94 (69%) 97.2 § 146.5
pN1 pN2 pN3 37 (27%) 122.9 § 130.2 0.067
Hormone receptor status
PgR-positive 102 (75%) 91.1 § 121.9
PgR-negative 34 (25%) 138.4 § 183.2 0.0332
HER2 status
Negative 106 (79%) 93.3 § 133.3
Positive 28 (21%) 143.9 § 162.6 0.0445123
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copies in IL-10 mRNA, for normal breast, total cancer
tissue, DCIS, pT1, and pT2, 3 stages, respectively (Fig. 1a, b).
FOXP3 and IL-10 mRNA expressions showed no corre-
lations with pN category, tumor histologic type, or lymphatic
invasion score (data not shown). However, FOXP3 mRNA
expression was positively correlated with tumor grade,
and also signiWcantly higher in PgR-negative cancers or
HER2-positive cancers (Table 2). Similarly, IL-10 mRNA
expression was positively correlated with PgR-negative
cancers or HER2-positive cancers (Table 2).
TGF1 and CCL22 mRNA expressions
We also used quantitative RT-PCR to analyze TGF1
and CCL22 mRNA expressions in breast cancer tissue
and compared expression levels against each clinicopath-
ological factor. TGF1 and CCL22 mRNA expressions
showed no correlation with pT category (data not
shown). However, TGF1 and CCL22 mRNA expres-
sions in cancer tissue were signiWcantly upregulated
when compared with normal breast tissue (P < 0.01),
even at the DCIS stage (P < 0.01) (Fig. 1c, d). TGF1
and CCL22 mRNA expressions were not correlated with
pN category, a tumor histologic type, tumor grade, lym-
phatic invasion score, hormone receptor status, or HER2
status, (data not shown).
Correlation between FOXP3 mRNA expression 
and expressions of IL-10, TGF1, and CCL22 mRNA
The relationships between FOXP3 mRNA expression and
expressions of IL-10, TGF1, and CCL22 mRNA were
analyzed (Fig. 2a–c). Positive correlations were observed
between expressions of FOXP3 and IL-10, FOXP3 and
TGF1, and FOXP3 and CCL22 mRNA (Spearman’s
 = 0.640, P < 0.0001;  = 0.307, P = 0.0004;  = 0.557,
P < 0.0001, respectively) (Fig. 2a–c).
Discussion
It has been reported that low level Foxp3 mRNA expression
is detectable in breast epithelium and breast cancer cell lines,
where Foxp3 functions as a breast cancer suppressor gene
[22], indicating attention to understand the origin of FOXP3-
expressing cells; those are breast epithelium, breast cancer
cells, or Treg cells. However, they demonstrated that
Fig. 1 FOXP3, IL-10, TGF1, 
and CCL22 mRNA expression 
in normal breast and cancer 
tissues. Clinical samples were 
subjected to quantitative 
RT-PCR analysis speciWc for 
FOXP3, IL-10, TGF1, and 
CCL22. Copy numbers of 





















































































Cancer Immunol Immunother (2009) 58:441–447 445deletion, functionally signiWcant somatic mutations, and down-
regulation of the FOXP3 gene were commonly found in
human breast cancer samples. In our study, it was observed
that FOXP3 expression was higher in tumor tissue than in
normal breast tissue. Together, it is strongly suggested that
the FOXP3 expression in breast cancer tissue, we observed
here, indicates the tumor-inWltrating Treg cell origin.
We hypothesized that Treg cell accumulation in tumor
tissue would be augmented in parallel with tumor progres-
sion. In this study, higher expression of FOXP3 mRNA in
tumor tissue than in normal breast tissue was observed even
at the DCIS stage and persisted at the T1 and T2, 3 stages,
indicating that Treg cell accumulation in tumor tissue is an
early event in tumor development and progression. Leong
et al. [23] have also shown the existence of Treg cells in
breast cancer tissue and that there is no signiWcant correla-
tion between tumor stage and CD4+CD25+ T cells,
although they have not mentioned about stage 0 (DCIS).
Interestingly, expression of CCL22, which has been shown
to be a ligand of CCR4 in Treg cells [20], was also found to
be higher in tumor tissue at the DCIS stage than in normal
breast tissue in our study. Miller et al. [24] have indicated
that Treg cells are an important cellular component of
early-stage prostate tumors, and that supernatants from cul-
tured prostate tissue samples and prostate cancer ascites
Xuid induce migration of Treg cells and contain the chemo-
kine CCL22 as detected by ELISA. It is therefore likely
that the homing receptors for Treg cells are induced and
expressed in tumor tissues at earlier phases of tumor devel-
opment, and the subsequent Treg cell accumulation helps
tumors to escape from the host immune system, resulting in
tumor progression.
Our further analysis showed that FOXP3 mRNA expres-
sion was upregulated in PgR-negative and Her2-positive
breast cancer tissues and signiWcantly correlated with tumor
grade. It has been reported that PgR status signiWcantly
improves outcome prediction over ER status alone for adju-
vant endocrine therapy of breast cancer patients [25]. HER-
2/neu gene ampliWcation and protein overexpression are
associated with worsened prognoses in patients with breast
cancer [26], even in DCIS tumors [27], suggesting the
involvement of FOXP3 expression as a prognostic factor in
breast cancer. Bates et al. [11] have investigated the expres-
sion of FOXP3 protein in breast cancer by immunohisto-
chemistry and demonstrated that high Treg cell numbers
are present in high-grade tumors, in patients with lymph
node involvement, and in ER-negative tumors, and HER2-
positive tumors, consistent with our observations, and that
breast cancer patients who express FOXP3 have poorer
prognoses. FOXP3-expressing Treg cells can avoid the
anti-tumor activity of immune eVector cells in breast cancer
tissue, resulting in poor prognosis of breast cancer patients.
Fig. 2 Regression analysis between FOXP3 mRNA expression and
IL-10, TGF1, CCL22 mRNA expressions. Copy numbers for FOXP3
mRNA were plotted in comparison with copy numbers for IL-10 (a),
TGF1 (b), and CCL22 (c) mRNA for each patient, and regression








































































446 Cancer Immunol Immunother (2009) 58:441–447It has been shown in some studies that Treg cells may
mediate immunosuppression through the secretion of IL-10
[28], and in other studies that TGF or direct cell-to-cell
contact may be important for suppression [29]. Gupta et al.
[12] have demonstrated that intratumoral FOXP3 mRNA
and protein levels were correlated with the levels of
TGF1, vascular endothelial growth factor and intratu-
moral microvessel density. In our study, FOXP3 expression
was positively correlated with IL-10 and TGF1 expression
in breast cancer tissue, and IL-10 was much more highly
correlated with FOXP3 expression than TGF1. This Wnd-
ing requires careful interpretation. IL-10 has been shown to
be secreted by not only Treg cells but also T helper-type
(Th)-2 cells [30]. In addition, it has been demonstrated that
tumor cells themselves can produce and secrete IL-10 pro-
tein [31], indicating that IL-10 expression in breast cancer
tissue does not always require Treg cells. TGF1 is also
produced from not only Treg cells, but many cell types
including tumor cells, and it is implicated in several aspects
of breast cancer onset and progression [32]. However, it has
been reported that Treg cells may stimulate Th-2 responses.
Suto et al. [33] reported that Treg cells induce Th-2 cell
proliferation in patients with allergic inXammation of the
airways. In previous studies of sentinel lymph node immu-
nity in breast cancer, we observed that upregulation of Treg
and Th-2 cell responses developed in parallel after metasta-
sis occurred in SNs [8]. Moreover, IL-10-producing Th-2
cells can regulate Th1 eVector cell function, resulting in
cancer-related imbalance of immune eVector cells [31, 32,
34]. Collectively, although the relationship between Treg
cells and IL-10 or TGF1 expression should be carefully
interpreted, our results may indicate that TGF1 and espe-
cially IL-10 are involved in Treg-associated immunosup-
pression in breast cancer tissues. To our knowledge, this is
the Wrst report showing a signiWcant correlation between
FOXP3 and IL-10 or TGF1 expression by regression anal-
ysis in breast cancer tissue in situ. IL-10 or TGF1 expres-
sion in breast cancer tissue in situ should be further
assessed in relation to Treg cells, Th2 cells, and tumor cells
because of the complexity of the tumor microenvironment.
This issue is an interesting question that is being currently
addressed in our institute.
Chemotherapeutic agents that attenuate Treg cell func-
tion may allow successful chemotherapy for breast cancer,
since Treg cells may play a large role in progression
of breast cancer. There are several types of combination
chemotherapy regimens for breast cancer treatment, and
representative protocols often contain an alkylating agent
cyclophosphamide [35]. Recent evidence has indicated
that cyclophosphamide reduces the number of Treg cells
[36, 37]. The chemotherapeutic activity of cyclophosphamide
may be dependent, in part, on the downregulation of Treg
cells in vivo. Bates et al. [11] have also pointed out the
requirement of targeting Treg cells in breast cancer treat-
ment for preventing late-relapses. More recently, not only
chemotherapeutic agents but also molecular targeting
agents including anti-CD25 [38], anti-GITR antibodies
[39], and IL-2-immunotoxin conjugates [40] have been
developed to eVectively attenuate Treg cell function. Our
results suggest that the success of these clinical investiga-
tions for Treg cell attenuation may enhance and improve
the eYcacy of breast cancer treatment in the future.
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